These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
115 related items for PubMed ID: 10813286
21. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Ann Clin Lab Sci; 2004; 34(4):423-6. PubMed ID: 15648784 [Abstract] [Full Text] [Related]
22. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830 [Abstract] [Full Text] [Related]
23. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. J Rheumatol; 2007 Sep; 34(9):1849-54. PubMed ID: 17659756 [Abstract] [Full Text] [Related]
25. Inflammation in patients with lupus anticoagulant and implications for thrombosis. Sailer T, Vormittag R, Pabinger I, Vukovich T, Lehr S, Quehenberger P, Panzer S, Lechner K, Zoghlami-Rintelen C. J Rheumatol; 2005 Mar; 32(3):462-8. PubMed ID: 15742437 [Abstract] [Full Text] [Related]
26. Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Hrycek A, Pochopień-Kenig G, Scieszka J. Autoimmunity; 2007 May; 40(3):217-22. PubMed ID: 17453721 [Abstract] [Full Text] [Related]
27. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus. Fragoso-Loyo HE, Sánchez-Guerrero J. J Rheumatol; 2007 Jan; 34(1):76-80. PubMed ID: 17143970 [Abstract] [Full Text] [Related]
28. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. Gilboe IM, Kvien TK, Husby G. J Rheumatol; 2001 Feb; 28(2):266-74. PubMed ID: 11246660 [Abstract] [Full Text] [Related]
29. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552 [Abstract] [Full Text] [Related]
30. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. Arthritis Rheum; 2003 Oct; 48(10):2888-97. PubMed ID: 14558095 [Abstract] [Full Text] [Related]
31. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus. Mak A, Cheung BM, Mok CC, Leung R, Lau CS. Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522 [Abstract] [Full Text] [Related]
32. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. J Rheumatol; 2000 Jul; 27(7):1681-5. PubMed ID: 10914851 [Abstract] [Full Text] [Related]
33. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus. Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM. J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157 [Abstract] [Full Text] [Related]
34. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. Wais T, Fierz W, Stoll T, Villiger PM. J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506 [Abstract] [Full Text] [Related]
35. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Garmendia M, Gabriel Erdozain J, Villar I, Aguirre C. Lupus; 2007 Oct; 16(10):810-6. PubMed ID: 17895304 [Abstract] [Full Text] [Related]
36. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics. Tao J, Dong J, Li Y, Liu YQ, Yang J, Wu Y, Li L, Shen GX, Tan ZJ, Tu YT. J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):433-7. PubMed ID: 19335730 [Abstract] [Full Text] [Related]
37. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus. Heshmat NM, El-Kerdany TH. Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298 [Abstract] [Full Text] [Related]
39. [Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome]. Reshetniak TM, Seredavkina nV, Mach ES, Aleksandrova EN, Novikov AA, Cherkasova MV, Nasonov EL. Ter Arkh; 2008 Aug; 80(10):60-7. PubMed ID: 19105418 [Abstract] [Full Text] [Related]
40. Impaired memory and learning abilities in patients with systemic lupus erythematosus as measured by the Rey Auditory Verbal Learning Test. Paran D, Litinsky I, Shapira-Lichter I, Navon S, Hendler T, Caspi D, Vakil E. Ann Rheum Dis; 2009 Jun; 68(6):812-6. PubMed ID: 18593761 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]